[go: up one dir, main page]

MX350718B - Vacuna de rinitis equina. - Google Patents

Vacuna de rinitis equina.

Info

Publication number
MX350718B
MX350718B MX2013010125A MX2013010125A MX350718B MX 350718 B MX350718 B MX 350718B MX 2013010125 A MX2013010125 A MX 2013010125A MX 2013010125 A MX2013010125 A MX 2013010125A MX 350718 B MX350718 B MX 350718B
Authority
MX
Mexico
Prior art keywords
equine rhinitis
equine
rhinitis vaccine
vaccine
virus
Prior art date
Application number
MX2013010125A
Other languages
English (en)
Other versions
MX2013010125A (es
Inventor
Wayne Hayes Phillip
J Hennessy Kristina
Viel Laurent
Diaz Mendez Andres
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of MX2013010125A publication Critical patent/MX2013010125A/es
Publication of MX350718B publication Critical patent/MX350718B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a composiciones inmunógenas contra virus de rinitis equina, en particular virus de rinitis equina A y B y métodos para su uso y su preparación. Las composiciones inmunógenas, en modalidades alternativas, también incluyen otros agentes patógenos de equinos.
MX2013010125A 2011-03-14 2012-03-12 Vacuna de rinitis equina. MX350718B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161452390P 2011-03-14 2011-03-14
US201161510226P 2011-07-21 2011-07-21
PCT/US2012/028706 WO2012125525A2 (en) 2011-03-14 2012-03-12 Equine rhinitis vaccine

Publications (2)

Publication Number Publication Date
MX2013010125A MX2013010125A (es) 2013-10-07
MX350718B true MX350718B (es) 2017-09-14

Family

ID=45876924

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010125A MX350718B (es) 2011-03-14 2012-03-12 Vacuna de rinitis equina.

Country Status (12)

Country Link
US (1) US9187730B2 (es)
EP (2) EP2772266B1 (es)
AR (1) AR085800A1 (es)
AU (2) AU2012229192B2 (es)
BR (2) BR122019023542B1 (es)
CA (2) CA3018230A1 (es)
ES (2) ES2842595T3 (es)
MA (1) MA35303B1 (es)
MX (1) MX350718B (es)
NZ (1) NZ614147A (es)
TW (1) TW201300537A (es)
WO (1) WO2012125525A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350718B (es) 2011-03-14 2017-09-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.
CA2967532A1 (en) 2014-11-24 2016-06-02 Intervet International B.V. Inactivated equine influenza virus vaccines
US10064930B2 (en) * 2015-01-16 2018-09-04 Boehringer-Ingelheim Vermedica, Inc. Immunogenic compositions and methods for pigeon fever
CN111447948A (zh) * 2017-12-04 2020-07-24 英特维特国际股份有限公司 具有复制子颗粒和油佐剂的疫苗

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
AUPN720195A0 (en) 1995-12-18 1996-01-18 University Of Melbourne, The Equine rhinovirus 1 proteins
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
AU2002253085B2 (en) 2001-02-28 2006-03-09 Intervet International B.V. Injectable water-in-oil emulsions
AU2002309508A1 (en) 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
AUPR472501A0 (en) 2001-05-02 2001-05-24 Council Of The Queensland Institute Of Medical Research, The Equine rhinitis a virus antigens
CN1935258B (zh) 2001-07-27 2013-04-03 惠氏公司 西尼罗河疫苗
NZ532385A (en) 2001-10-19 2007-01-26 Acambis Inc Methods of preventing and treating flavivirus infection in animals
EP1575979B1 (en) 2002-11-15 2009-12-23 Sanofi Pasteur Biologics Co. West nile virus vaccine
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
EP1664786B1 (en) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7459163B2 (en) 2004-02-25 2008-12-02 University Of Kansas Infectious DNA as a vaccine against west nile and other flaviviruses
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
EP1645283A1 (en) 2004-10-08 2006-04-12 Chiron Behring GmbH & Co. KG Combination vaccine
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
AU2006261943B2 (en) 2005-06-24 2010-12-02 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
US7384642B2 (en) 2005-08-25 2008-06-10 Merial Limited Canine influenza vaccines
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
WO2007042884A1 (en) 2005-10-07 2007-04-19 Pfizer Products Inc. Vaccines and methods to treat canine influenza
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
AU2006310555B2 (en) 2005-11-01 2011-08-04 Intervet International B.V. Prime boost vaccine for the protection of equines against equine influenza
US7455842B2 (en) 2005-12-05 2008-11-25 University Of Kansas Chimeric West Nile viruses and uses thereof
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
EP2334327B1 (en) 2008-08-29 2016-01-06 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
MX350718B (es) 2011-03-14 2017-09-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.

Also Published As

Publication number Publication date
NZ708320A (en) 2016-08-26
AU2012229192A1 (en) 2013-08-29
ES2842595T3 (es) 2021-07-14
WO2012125525A2 (en) 2012-09-20
CA3018230A1 (en) 2012-09-20
AU2012229192B2 (en) 2017-04-20
TW201300537A (zh) 2013-01-01
CA2829226A1 (en) 2012-09-20
BR112013023354A2 (pt) 2016-12-06
NZ614147A (en) 2015-08-28
MA35303B1 (fr) 2014-08-01
AR085800A1 (es) 2013-10-30
MX2013010125A (es) 2013-10-07
EP2772266B1 (en) 2019-07-31
WO2012125525A3 (en) 2013-02-28
US20120237543A1 (en) 2012-09-20
EP2772266A1 (en) 2014-09-03
AU2017201526B2 (en) 2019-07-18
ES2748555T3 (es) 2020-03-17
US9187730B2 (en) 2015-11-17
EP2686012A2 (en) 2014-01-22
BR112013023354B1 (pt) 2022-02-15
CA2829226C (en) 2023-01-03
EP2686012B1 (en) 2020-12-02
AU2017201526A1 (en) 2017-03-30
AU2017201526C1 (en) 2019-10-24
BR122019023542B1 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
MX342716B (es) Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
IL215430A (en) Immunogenic and antiviral vaccines and their use
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
ZA201308461B (en) Multiple antigen presenting immunogenic composition and methods and uses thereof
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MD4589B1 (ro) Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
TW201144301A (en) Processes for preparing linezolid
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
MX346596B (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2013177444A3 (en) Influenza vaccine constructs
SG11201504805PA (en) Porcine parvovirus 5a, methods of use and vaccine
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2013052095A3 (en) Vaccine
MX350718B (es) Vacuna de rinitis equina.
IL238023A0 (en) Uncrosslinked pertussis antigens for use in combination formulations
MX2017015004A (es) Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
PL2569007T3 (pl) Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
PL3076996T3 (pl) Szczepionka przeciwko cirkowirusowi świń typu 2
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF

Legal Events

Date Code Title Description
FG Grant or registration